Amarantus Bioscience - AMBS. The company's patented MANF technology will benefit substantially from the "Brain Mapping Project".
"Big pharma" joint venture or partnership is likely this year.
One of the co-founders of Amgen is on the company's advisory board.
Read the recent Yahoo news.
Due diligence on AMBS. It's substantially undervalued here.
500% upside within 3 months.